RBC Capital Markets Raises Price Target on Acadia Pharmaceuticals
RBC Capital Markets increased its price target for Acadia Pharmaceuticals to $41 from $31 while maintaining an Outperform rating.
Stocks · News reference
RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $36
RBC Capital Markets increased its price target for Acadia Pharmaceuticals to $38 from $36 while maintaining an 'Outperform' rating, citing continued momentum for the drug Daybue.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting total revenues of $342 million.
ACADIA Pharmaceuticals Q3 EPS $0.31 Beats $0.20 Estimate, Sales $342.291M Beat $332.468M Estimate
8-K filing — ACADIA PHARMACEUTICALS INC (ACAD)
Filed: 2026-11-04 AccNo: 0001193125-26-447276 Size: 525 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
AcadeMedia Releases Interim Report for Q1 2026/27
AcadeMedia AB (publ) has published its interim report for the first quarter of the 2026/27 fiscal year.
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Acadia Pharmaceuticals announced its participation in a fireside chat at the upcoming UBS Global Biopharma Conference 2026.